Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Bio-Techne Corp’s stock clocked out at $53.42, down -2.21% from its previous closing price of $54.63. In other words, the price has decreased by -$2.21 from its previous closing price. On the day, 1.74 million shares were traded. TECH stock price reached its highest trading level at $54.38 during the session, while it also had its lowest trading level at $52.31.
Ratios:
To gain a deeper understanding of TECH’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 51.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.39. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 3.46. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.22.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 25 ’25 when Nusse Roeland sold 17,040 shares for $56.36 per share. The transaction valued at 960,388 led to the insider holds 44,559 shares of the business.
BAUMGARTNER ROBERT V sold 17,040 shares of TECH for $957,818 on Aug 25 ’25. The Director now owns 44,863 shares after completing the transaction at $56.21 per share. On Aug 25 ’25, another insider, ROELAND NUSSE, who serves as the Director of the company, bought 17,040 shares for $56.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TECH now has a Market Capitalization of 8309480960 and an Enterprise Value of 8591331328. As of this moment, Bio-Techne’s Price-to-Earnings (P/E) ratio for their current fiscal year is 117.79, and their Forward P/E ratio for the next fiscal year is 23.61. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 10.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.81 while its Price-to-Book (P/B) ratio in mrq is 4.31. Its current Enterprise Value per Revenue stands at 7.044 whereas that against EBITDA is 25.945.
Stock Price History:
The Beta on a monthly basis for TECH is 1.47, which has changed by -0.24887514 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, TECH has reached a high of $80.95, while it has fallen to a 52-week low of $46.01. The 50-Day Moving Average of the stock is -0.43%, while the 200-Day Moving Average is calculated to be -11.37%.
Shares Statistics:
It appears that TECH traded 2.30M shares on average per day over the past three months and 2008450 shares per day over the past ten days. A total of 154.97M shares are outstanding, with a floating share count of 153.75M. Insiders hold about 1.16% of the company’s shares, while institutions hold 103.03% stake in the company. Shares short for TECH as of 1755216000 were 5772492 with a Short Ratio of 2.51, compared to 1752537600 on 6530665. Therefore, it implies a Short% of Shares Outstanding of 5772492 and a Short% of Float of 4.29.
Dividends & Splits
With its trailing 12-month dividend rate of 0.32, TECH has a forward annual dividend rate of 0.32. Against a Trailing Annual Dividend Yield of 0.0058575873The stock’s 5-year Average Dividend Yield is 0.41. The current Payout Ratio is 69.67% for TECH, which recently paid a dividend on 2025-08-18 with an ex-dividend date of 2025-08-18. Stock splits for the company last occurred on 2022-11-30 when the company split stock in a 4:1 ratio.
Earnings Estimates
The market rating for Bio-Techne Corp (TECH) is a result of the insights provided by 13.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.46, with high estimates of $0.5 and low estimates of $0.43.
Analysts are recommending an EPS of between $2.13 and $1.91 for the fiscal current year, implying an average EPS of $2.02. EPS for the following year is $2.24, with 12.0 analysts recommending between $2.44 and $2.01.
Revenue Estimates
In the current quarter, 13 analysts expect revenue to total $293.06M. It ranges from a high estimate of $298M to a low estimate of $289.52M. As of the current estimate, Bio-Techne Corp’s year-ago sales were $289.46MFor the next quarter, 13 analysts are estimating revenue of $300.69M. There is a high estimate of $309.5M for the next quarter, whereas the lowest estimate is $296.13M.
A total of 15 analysts have provided revenue estimates for TECH’s current fiscal year. The highest revenue estimate was $1.26B, while the lowest revenue estimate was $1.23B, resulting in an average revenue estimate of $1.24B. In the same quarter a year ago, actual revenue was $1.22BBased on 12 analysts’ estimates, the company’s revenue will be $1.33B in the next fiscal year. The high estimate is $1.36B and the low estimate is $1.29B.
